WALD Stock Forecast & Price Target

Waldencast is facing challenges due to the ongoing SEC investigation and caution towards the Milk Makeup segment, leading to lower revenue and earnings expectations for FY25. However, the company's strong performance in the Obagi Medical segment and ongoing strategic review to maximize shareholder value show potential for future growth. The recent credit agreement and sale of the Obagi Japan trademark rights also demonstrate efforts towards improving financial stability. Overall, the long-term growth potential of the company's brands and its consistent revenue generation from the North America region present a positive outlook for Waldencast's stock.

Waldencast is facing several challenges that have contributed to a negative outlook on its stock. These include slower than expected growth in its Milk Makeup segment, with softer demand in international markets and inventory-related adjustments. In addition, the company's strategic review efforts have not yet yielded significant improvements in terms of profitability and market value. Finally, there are a number of industry-specific risks, such as volatility in commodity costs and the impact of geopolitical uncertainty, that could continue to hinder the company's performance.